SV Life Sciences Fund II (SVLSFII)

SVLSF II closed in 1999 with total commitments of $280 million (plus $30 million of co-investments committed by partners and individuals affiliated with SVLS).

As at 31 December 2006, SVLSF II had invested $315 million (including re-investment) in 36 portfolio companies.

To go to individual portfolio companies websites please click on company logo.


Achillion: US

First investment: 2000 - Start Up

Dedicated to bringing important new treatments to patients with infectious disease. Anti-infective drug development.

---

Aderis Pharmaceuticals: US

First investment: 2001 - Expansion - Exited

Cardiovascular, renal and neurological disease focused therapeutics focused upon making a significant difference to people living with cardiovascular, renal and neurological diseases.

---

Affibody: Sweden

First investment: 2001 - Early Stage

Molecular imaging and targets therapeutics.

---

Auxilium Pharmaceuticals: US

First investment: 2001 - Early Stage

Male Hormone Replacement Therapy.

---

Cellzome: Germany

First investment: 2001 - Start Up

Proteomics technology for target and lead identification, and a drug discovery program in Alzheimer's Disease.

---

Cognis: Luxembourg

First investment: 2001 - Buy Out

Speciality chemicals. Products and solutions for personal care, home care and modern nutrition.

---

Eyetech Pharmaceuticals: US

First investment: 2000 - Early Stage - Exited

Bought by OSI Pharmaceuticals after our exit. Opthalmolological drug development.

---

Ingenium: Germany

First investment: 2000 - Early Stage

Functional genomics and drug development.

---

KuDOS Pharmaceuticals: UK

First investment: 1999 - Start Up - Exited

Oncology drug development.

---

Lorantis: UK

First investment SVLSF II: 2000 - Start Up
First investment SVLSF III: 2003 - Early Stage

Previously known as Lorantis. Immunology based drugs.

---

Metris Therapeutics: UK

First investment SVLSF I: 1998 - Start Up
First investment SVLSF II: 2000 - Start Up

Treatment of gynaecological disorders.

---

Orchid Chemicals and Pharmaceuticals: India

Private investment in Public Equity
First investment: 1999 - Expansion - Exited

Manufacture of bulk generic pharmaceuticals.

---

Oxagen: UK

First investment: 2000 - Expansion

Clinical genomics.

---

Quantum Dot: US

First investment: 2000 - Early Stage - Exited

Nanocrystal biological reagents.

---

Solexa: UK

First investment: 2001 - Start Up

Ultra high throughput DNA sequencing.

---

Third Wave Technologies: US

First investment: 1999 - Expansion - Exited

Products for analysing genetic variations

---

Trine Pharmaceuticals: US

First investment: 2001 - Expansion

Anti-infective drug discovery. (Formerly known as Essential Therapeutics 'ETRX')

---

Versicor: US

First investment: 1999 - Expansion - Exited

Drug development for infectious diseases (Changed name to Vicurion Pharmaceuticals in 2003)